Literature DB >> 14991630

Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding.

S González-Moreno1, P H Sugarbaker.   

Abstract

BACKGROUND: Traditionally epithelial malignancies of the appendix with or without carcinomatosis have been treated by right hemicolectomy. Recent accumulation of a large number of patients with this disease has enabled a re-evaluation of this surgical judgement.
METHODS: Clinical data on 501 patients with epithelial malignancy of the appendix were collected prospectively. All patients had peritoneal seeding at the time of referral and were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. The main independent variable for statistical analysis was the surgical procedure used to resect the primary cancer (appendicectomy alone versus right hemicolectomy). Nineteen other clinical and pathological variables were considered as control variables. The endpoint for all analyses was survival.
RESULTS: Median follow-up after the initial diagnosis was 4 years. The rate of regional lymph node positivity was 5.0 per cent. When the incidence of lymph node metastasis was determined by histological type, it was statistically significantly higher in intestinal (66.7 per cent) than in mucinous (4.2 per cent) tumours (P < 0.001). The presence of lymph node metastases had no influence on prognosis (P = 0.155). The surgical procedure (appendicectomy alone versus right hemicolectomy) had an influence on patient survival by univariate analysis (P < 0.001), but not by multivariate analysis (P = 0.258).
CONCLUSION: Right hemicolectomy does not confer a survival advantage in patients with mucinous appendiceal tumours with peritoneal seeding. These data suggest that right hemicolectomy should be avoided unless metastatic involvement of the appendiceal or distal ileocolic lymph nodes is documented by biopsy, or the resection margin is inadequate. Copyright 2004 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 14991630     DOI: 10.1002/bjs.4393

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  60 in total

1.  Primary appendiceal mucinous adenocarcinoma alongside with situs inversus totalis: a unique clinical case.

Authors:  Athanasios Petrou; Alexandros Papalambros; Nikolaos Katsoulas; Konstantinos Bramis; Konstantinos Evangelou; Evaggelos Felekouras
Journal:  World J Surg Oncol       Date:  2010-06-04       Impact factor: 2.754

2.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

3.  Appendiceal adenocarcinoma presenting as venous thromboembolism: an unusual presentation of a rare carcinoma.

Authors:  Jason A Castellanos; Christina M Edwards; Aaron Shaver; Nipun B Merchant; Alexander A Parikh
Journal:  Am Surg       Date:  2010-05       Impact factor: 0.688

4.  Appendiceal mucocoeles and pseudomyxoma peritonei.

Authors:  Anupam Dixit; John H P Robertson; Satvinder S Mudan; Charles Akle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

5.  Safety and feasibility of laparoscopic surgery for appendiceal mucocele: a multicenter study.

Authors:  Tae Kyu Kim; Jun Ho Park; Jeong Yeon Kim; Byung Chun Kim; Byung Mo Kang; Soo Kee Min; Jong Wan Kim
Journal:  Surg Endosc       Date:  2018-04-13       Impact factor: 4.584

6.  Pseudomyxoma peritonei masquerading as ascites secondary to alcoholic cirrhosis.

Authors:  Tu Nguyen; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2009-07-02       Impact factor: 3.199

7.  Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre.

Authors:  Álvaro Arjona-Sánchez; Francisco C Muñoz-Casares; Sebastián Rufián-Peña; Rafael Díaz-Nieto; Ángela Casado-Adam; María J Rubio-Pérez; Rosa Ortega-Salas
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

8.  Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival.

Authors:  Patrick L Wagner; Frances Austin; Ugwuji Maduekwe; Arun Mavanur; Lekshmi Ramalingam; Heather L Jones; Matthew P Holtzman; Steven A Ahrendt; Amer H Zureikat; James F Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

9.  Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  Alvaro Arjona-Sanchez; Francisco Cristobal Muñoz-Casares; Angela Casado-Adam; Juan Manuel Sánchez-Hidalgo; Maria Dolores Ayllon Teran; Rafael Orti-Rodriguez; Ana Cristina Padial-Aguado; Javier Medina-Fernández; Rosa Ortega-Salas; Gema Pulido-Cortijo; Auxiliadora Gómez-España; Sebastián Rufián-Peña
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

10.  Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.

Authors:  Tommaso Cioppa; Marco Vaira; Camilla Bing; Silvia D'Amico; Alessandro Bruscino; Michele De Simone
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.